Houston nonprofit news outlet will shut down after only 2 years

In the News

Houston Landing, a nonprofit news organization, will cease operations next month. Photo via Getty Images

Amid financial challenges, the nonprofit Houston Landing online news outlet plans to shut down by mid-May.

In an April 15 announcement posted on its website, Houston Landing says that although it launched in 2023 with more than $20 million in seed funding, the outlet failed to attract enough revenue to continue operating. The announcement followed a vote by the organization’s board of directors to close the nonprofit newsroom. All 43 employees will be laid off, the Columbia Journalism Review reports.

“We are proud of the Landing’s coverage of Greater Houston and continue to believe deeply in the need for more free, independent journalism in our region,” Ann B. Stern, board chair of Houston Landing as well as president and CEO of the Houston Endowment, says in the announcement. “This decision was difficult but necessary. Houston Landing’s reporting has made a meaningful impact in the community, but it struggled to find its long-term financial footing.”

According to the announcement, the Landing’s board is exploring a partnership with the Austin-based Texas Tribune, a pioneer in nonprofit journalism, to potentially establish a local news initiative in Houston. Later this year, the Texas Tribune plans to open a locally focused newsroom in Waco. A similar newsroom is in the works in Austin.

“We have great respect for Houston Landing’s work in delivering high-quality, nonpartisan journalism to its readers,” says Sonal Shah, CEO of the Texas Tribune. “We also understand the profound challenges facing local newsrooms today — journalism is a public service and needs a strong ecosystem to thrive. We look forward to exploring how we can learn from what the Landing started and create a sustainable model that serves the Houston community. We will take time to explore the right path forward to ensure sustainability.”

Houston Landing was launched after a two-year study led by the American Journalism Project found many Houstonians were disappointed about a lack of trustworthy, deeply reported local news. Financial backers of the Landing include the American Journalism Project, the Houston Endowment, Arnold Ventures, the Kinder Foundation, and the John S. and James L. Knight Foundation.

Despite the high-profile support, the site struggled to find an audience. CJR notes that the Landing had approximately 13,000 newsletter subscribers and only generated about $80,000 in subscription revenue. In the article, executive editor Sewell Chan identifies a number of other issues, including a lack of editorial focus and changes in leadership. “But in the end, the gap between board and staff, between management and labor, and between runway and revenue was just too large to bridge,” he writes.

“While it’s with a heavy heart that we announce the closure of our newsroom, I want to express my deepest gratitude to the dedicated journalists and staff members who poured their passion into our mission every single day,” Houston Landing CEO Peter Bhatia says.

“Houston Landing demonstrates how a commitment to truth and accountability can transform communities and improve lives,” he adds. “I’m thankful to those who believed in us, supported us, and stood with us as we connected with each other through stories that inspired positive change.”

---

This article originally appeared on our sister site, CultureMap.com.

Ashley Small, founder and CEO of Medley Inc., joins the Houston Innovators Podcast this week to discuss COVID-19's affect on her business and fostering diversity at startups. Photo courtesy of Medley Inc.

Houston founder calls for business leaders to 'make room for diverse voices'

HOUSTON INNOVATORS PODCAST EPISODE 70

Last year was one of quick pivots and tech solutions for Ashley Small and her company's clients. Small — the CEO and founder of Medley Inc., a Houston-based branding and public relations firm — works with both for-profit and nonprofit entities to tell their stories, and of course 2020 had its challenges in doing so. But they weren't anything Small, her team, and technology couldn't overcome.

Small founded Medley over 12 years ago, and for the past three of those years, her team has been completely virtual. She shares on the Houston Innovators podcast that this give her team a headstart on being able to find and quickly adopt quick tech solutions — but last year's shutdown also meant navigating this for all her clients.

"The biggest obstacle we had to overcome was figuring out what the best technology was for each client," Small says. "Where the learning curve has been is understanding all the available resources out there and understanding how offline experiences can help audiences connect online."

Founded in Houston, Medley has grown to the Los Angeles and Chicago markets over the years — and Small says that was intentional. An Oklahoma native, Small fell in love with Houston's diversity when she attended Texas Southern University, and sought out other diverse markets to expand her business. And, as a Black female founder, she fosters an inclusive community at her company — and wants to remind her fellow business owners how imperative it is to running an innovative company.

"Innovation is actually impossible without diversity," Small says, adding that when you bring different people to the table, you get new ways of thinking. "A part of this is also being really open minded to the fact that you are going to hear ideas that sound and look different. Be open to that, because that is 100 percent the point."

Small knows early-stage companies aren't always able to hire a bunch of people from diverse backgrounds right from the start, but there are other ways to surround yourself with diverse ideas.

"Make room for diverse voices -- and you may have to be a bit creative," Small says.

Medley's team also realizes that not every startup can afford to bring on an in-house or third-party PR team, but the company has a few options for startups, such as a three-month retainer to start as well as a series of workshops available online for as low as $19.

Small discusses more about how she's honoring Black History Month with her team and the evolution the PR and media industries have seen over the past decade on the episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings